Eupraxia Pharmaceuticals Inc. (TSX:EPRX)

Canada flag Canada · Delayed Price · Currency is CAD
8.54
+0.48 (5.96%)
At close: Dec 5, 2025
90.62%
Market Cap 432.54M
Revenue (ttm) n/a
Net Income (ttm) -44.17M
Shares Out 50.65M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 122,078
Average Volume 86,538
Open 8.24
Previous Close 8.06
Day's Range 8.15 - 8.72
52-Week Range 3.96 - 9.88
Beta 1.50
RSI 50.75
Earnings Date Nov 7, 2025

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 33
Stock Exchange Toronto Stock Exchange
Ticker Symbol EPRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.